2568 Pembrolizumab for patients with leptomeningeal disease from advanced solid tumors

OBJECTIVES/SPECIFIC AIMS: Pembrolizumab is an anti-PD-1 immune checkpoint antibody that has demonstrated promising anti-tumor activity in patients with solid tumor malignancies, including patients with brain metastases from malignant melanoma and non-small cell lung cancer. Leptomeningeal disease (L...

Descripción completa

Detalles Bibliográficos
Autores principales: Naidoo, Jarushka, Hu, Chen, Schrek, Karisa, Connolly, Roisin, Santa-Maria, Cesar, Lipson, Evan, Mehra, Ranee, Bettegowda, Redmond, Kristin, Venkatesan, Arun, Grossman, Stuart
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2018
Materias:
Basic/Translational Science/Team Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6799477/
http://dx.doi.org/10.1017/cts.2018.174

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6799477/
http://dx.doi.org/10.1017/cts.2018.174

Ejemplares similares